secwatch.observer — SEC 8-K summary
======================================

Issuer:     InspireMD, Inc. (NSPR)
CIK:        0001433607
Form:       8-K
Filed at:   2024-03-06T23:59:59+00:00
Accession:  0001493152-24-008941
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

InspireMD Q4 revenue jumps 71.6% to $1.76M; net loss $0.16 per share
--------------------------------------------------------------------

- Record Q4 CGuard EPS revenue of $1.76M, up 71.6% YoY; 3,107 stents sold (+74.5%).
- C-GUARDIANS trial showed 0.95% DSMI rate at 30 days; PMA submission expected mid-2024.
- CE Mark recertified under EU MDR, enabling new product development pathway.
- CMS expanded CAS coverage to asymptomatic and standard-risk patients, widening U.S. market.
- Cash and equivalents $39.0M at Dec 31, 2023, up from $17.8M a year earlier.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1433607/000149315224008941/0001493152-24-008941-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1433607/000149315224008941/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-008941

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer